Cardiac transplantation. Selection, immunosuppression, and survival

Area of Science:

• Cardiology
• Immunology
• Transplantation Medicine

Background:

• Cardiac transplantation has transitioned from experimental to accepted therapy for end-stage heart failure.
• Increasing demand for donor organs necessitates optimized recipient selection and timing.
• Aggressive medical management is crucial for patients awaiting or undergoing transplantation.

Purpose of the Study:

• To review the current state of cardiac transplantation, including donor-recipient matching and immunosuppressive strategies.
• To highlight advancements in histocompatibility assessment and the role of cyclosporine.
• To discuss outcomes, challenges, and quality of life post-transplantation.

Main Methods:

• Review of current practices in cardiac transplantation.
• Analysis of histocompatibility testing, distinguishing autoantibodies from human leukocyte antigen reactivity.
• Evaluation of cyclosporine therapy and potential synergistic approaches.
• Assessment of post-transplant outcomes, including survival rates and common complications.

Main Results:

• Recipient and donor pools are expanding, improving opportunities for histocompatibility assessment.
• Cyclosporine therapy has enhanced post-transplant outcomes, though further optimization is needed to balance efficacy and toxicity.
• One-year survival exceeds 80%, with declining rates of acute rejection and infection.
• Accelerated atherosclerosis emerges as a significant long-term concern.

Conclusions:

• Cardiac transplantation offers excellent long-term quality of life for patients with severe heart failure.
• Continued refinement of immunosuppression and management of long-term complications like atherosclerosis are essential.
• Optimized donor-recipient matching and medical therapy are key to successful cardiac allograft survival.